|
LINE1 CpG site
|
# events/# patients*
|
Extent methylation†
|
HR‡
|
95% CI; P value
|
HRcont.§
|
95% CI; P value
|
|---|
|
CpG1
|
13/21
|
<25.68
|
1**
| |
1.51
|
1.06-2.16; 0.02
|
| |
17/21
|
≥25.68
|
1.57
|
0.76-3.24; 0.22
| | |
|
CpG2
|
12/21
|
<27.26
|
1
| |
1.60
|
1.02-2.52; 0.04
|
| |
18/21
|
≥27.26
|
2.12
|
1.01-4.44; 0.04
| | |
|
CpG3
|
11/21
|
<40.46
|
1
| |
1.49
|
1.06-2.09; 0.02
|
| |
19/21
|
≥40.46
|
2.63
|
1.21-5.69;. 0.01
| | |
- * number of patients who died (# events) and total number of patients in the group (# patients) are reported;
- † Patients were divided according to the % of methylation of the specified CpG site being <or ≥ the median % methylation measured in the examined patients' population;
- ‡ Cox proportional hazard method was used to examine the effect of LINE-1 methylation on OS. Results were presented as Hazard Ratios (HR) with corresponding 95% Confidence Intervals (CI);
- § LINE-1 methylation was also evaluated as continuous variable. The HR value is that of the LINE-1 methylation relative to an increase of 10%;
- ** set as reference.
